Alzheimer's Disease: 5 Stocks On Biotech Radars

(Video length 00:13:45)

Thursday concludes the American Academy of Neurology (AAN) 2021 virtual conference where hundreds of researchers from companies, universities, and other labs presented over 2,000 scientific abstracts in multiple formats.

The annual meeting provides the space for thousands of neurology professionals -- neurologists and neuroscientists -- to learn about scientific breakthroughs and cutting-edge therapeutics in areas ranging from stroke and brain tumors to sleep disorders, depression, and migraines.

One of the highlights for a public company, Jazz Pharmaceuticals (JAZZ Quick Quote JAZZ - Free Report), was in their Phase 3 data for Xywav in the treatment of a sleep disorder called idiopathic hypersomnia (IH). Jazz has already built a very successful business on their narcolepsy drug Xyrem and recently made an agreement to acquire GW Pharmaceuticals, the only company with an FDA-approved medicine derived from cannabis, for approximately $7.5 billion.

In the video that accompanies this article, I go over the charts of several public companies involved in dedicated R&D to treat Alzheimer's Disease (AD), including Biogen (BIIB Quick Quote BIIB - Free Report). Alzheimer's is the holy grail right now in neurology and diseases of the central nervous system (CNS) because as a form of rapid, non-normal dementia, it is considered especially pernicious as it progresses so quickly in destroying memory.

And because the precise cause of the disease is still unknown, with much research concentrating on the protein amyloid plaques found in brain tissue, no lab or company has developed an efficacious treatment yet. In fact, even the giant Pfizer gave up the hunt a few years ago.

Aducanumab is Biogen's proposed treatment candidate for early AD that is intended to slow the progression of the disease. With research success often imminent and then fleeting, the stock has been whipping like a rollercoaster between $220 and $380 for nearly four years.

1 2 3 4
View single page >> |

Kevin Cook is a Senior Stock Strategist for Zacks Investment Research where he runs the TAZR Trader and more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Oliver Randy 2 weeks ago Member's comment

I was diagnosed with Fibromyalgia years ago after long treatment with various drugs (illness progress whole that time). Horrible disease.

Samantha Wolf 3 weeks ago Member's comment

What about $ANVS?